Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
|Articles|April 15, 2002
- BioPharm International-04-01-2002
- Volume 15
- Issue 4
Outsourcing Outlook: Public CROs Craft New Strategies to Achieve Financial and Strategic Objectives
Author(s)Jim Miller
by Jim Miller, PharmSource Information Services, Inc. Tough economic times have prompted CROs to reflect on their past performance and to create potential solutions for the future.
Advertisement
Articles in this issue
over 24 years ago
Analytical Advances: Paperless or Less Paper?over 24 years ago
Beyond QSITover 24 years ago
Determining Protein Concentration, Part 1: Methodologyover 24 years ago
Guest Editorial: The Protein Production Challengeover 24 years ago
Business Matters: Personalized Medicine or Blockbusterology?over 24 years ago
Advances in Amino Acid AnalysisAdvertisement
Related to this article
ADC trials are moving from binary antigen testing to quantitative, multiparameter biomarker models that better predict efficacy and toxicity.
Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.
Advertisement
Advertisement
Trending on BioPharm International
1
China Grants Ivonescimab Priority Review in Biliary Tract Cancer
2
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
3
Caldera’s IL-23p19×TL1A Bispecific CLD-423 Shows 40-Day Half-Life in Phase 1a, Supporting Dosing Every 8 to 12 Weeks
4
VeonGen Aligns with FDA on Phase 3 Design for Stargardt Gene Therapy
5